Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Biotechs Strike Out Across Europe

Executive Summary

U.S. biotech companies are showing greater interest in building commercial infrastructure in Europe, in order to bring new medicines to European customers without local partners. Switzerland is a popular location, because of its position in the center of the continent, but the presence of experienced management is also important.

You may also be interested in...



Sanofi Oncology’s Transformation Rests On Fedratinib, At Least In The Near-Term

The JAK2 inhibitor for myelofibrosis is the company’s most advanced oncology candidate and will be an anchor for Sanofi as it looks to build a portfolio of next-generation cancer drugs after the late-stage failure of the PARP inhibitor iniparib.

Europe’s CHMP Okays Xtandi, Erivedge And Spedra, But Rejects Xeljanz

Two new cancer therapies – Astellas’ prostate cancer drug Xtandi and Roche’s basal cell carcinoma drug Erivedge – have been cleared for European approval by the CHMP scientific advisory panel. It also backed Vivus’ erectile dysfunction therapy Spedra and Avanir’s emotional outburst therapy, Nuedextra, but turned down Pfizer’s JAK inhibitor Xeljanz.

Alimera Resubmits Iluvien In U.S. As It Begins EU Launch

The Atlanta-based ophthalmology company hopes to succeed in third try with FDA, but must split its focus with Europe as it tries to roll out launches in several countries at once.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel